Mobile

An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatment...

Update Il y a 4 ans
Reference: EUCTR2007-007081-38

An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatment of Subjects With Advanced Colorectal Cancer

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess if the addition of oral ABT-869 to mFOLFOX6 (5-fluorouracil, folinic acid, and oxaliplatin) can prolong progression-free survival (PFS) compared to bevacizumab plus mFOLFOX6 as second-line treatment in subjects with advanced colorectal cancer.

Inclusion criteria

  • Advanced colorectal cancer

Links